Abstract
Top of pageAbstract A live attenuated mumps vaccine (Jeryl-Lynn strain) was evaluated in a field trial which included more than 2300 children who had no previous history of mumps. The objectives were to study antigenic potency and side effects of the vaccine. Parents of vaccinees recorded daily temperatures and other symptoms on a card which was returned. Paired serum specimens were obtained at the time of vaccination and one month later from 1202 children. The results to date indicate: 1. 45 % of 592 children who had no history of having mumps had detectable serum antibody before vaccination; 2. 98% of 340 seronegative vaccinees had 4-fold or greater antibody response; 3. the vaccination was tolerated very well; the incidence of febrile responses and of clinical symptoms was essentially the same in 335 successfully vaccinated children as compared with 252 children who were immune prior to vaccination. These studies indicate that the vaccine is antigenically potent and is clinically acceptable. (SPR)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
